In more recently performed clinical trials, recombinant IFN-γ (actimmune or IFN-γ1b) and adenovirus vectors expressing IFN-γ cDNA have been used for treatment of a variety of disorders, including cancer, tuberculosis, hepatitis, osteopetrosis and scleroderma [119]. Here, IFNG is linked to scleroderma.